Gefticip Tablet

Gefticip is indicated for patients with locally advanced or metastatic NSCLC harboring specific EGFR mutations, particularly exon 19 deletions or exon 21 (L858R) substitution mutations. The medication is administered once daily, with or without food, and requires careful patient selection based on molecular diagnostic testing to ensure efficacy. Common adverse effects include diarrhea, rash, acneiform dermatitis, and elevated liver enzymes, necessitating regular monitoring of hepatic function and clinical status.

Caution is advised in patients with pre-existing interstitial lung disease or hepatic impairment. Gefticip should be used under oncological supervision, with periodic assessment of tumor response and toxicity. Dose adjustments or discontinuation may be required in cases of severe adverse reactions. This targeted therapy represents a significant advancement in personalized cancer treatment, improving progression-free survival in EGFR-mutated NSCLC patients.